You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

Dermatology

European Academy of Allergy and Clinical Immunology (EAACI) 2023 | Hamburg

Presentation highlights from the ADVENT symposium at the EAACI 2023 congress in Hamburg, Germany.

Stephan Weidinger

Peter Arkwright

Oscar Palomares

MD, PhD

Stephan Weidinger +7 more

Past event

9June2023

Location

Congress Center Hamburg CCH

Hamburg Germany

Learning objectives

Examine the multidimensional disease burden in children with AD and their families/caregivers, and the impact of type 2 comorbidities
Learn about the impact of targeting type 2 inflammation in children with AD, from the normalization of the skin barrier to the improvement of bone mineralization markers
Provide an overview of the treatment landscape in children with AD, and examine updates on clinical trials of dupilumab

Description

Targeting Type 2 Inflammation in Children With Atopic Dermatitis: Opportunity for Early Intervention?
- In this ADVENT symposium at the 2023 EAACI congress, “Targeting Type 2 Inflammation in Children With Atopic Dermatitis: Opportunity for Early Intervention?”, Stephan Weidinger, MD, PhD (University Hospital Schleswig-Holstein), Peter Arkwright, MD, PhD (University of Manchester), and Oscar Palomares, PhD (University of Madrid), discussed the multidimensional disease burden of atopic dermatitis in children, the pathophysiology of the disease driven by type 2 inflammation, and the current treatment landscape for pediatric patients with atopic dermatitis.

Location

Congress Center Hamburg CCH

Hamburg Germany

Tags

quality of life biologics jak inhibitors pediatric symposium mechanism of disease

-

Speakers

Stephan Weidinger

Professor and Chair for Dermatology at the Christian-Albrechts-University; Director of the Department of Dermatology and Allergy at the University Hospital Schleswig-Holstein, Campus Kiel, Germany

Allergy/Immunology

Peter Arkwright

Senior Lecturer/Consultant in Paediatric Allergy and Immunology at the University of Manchester and Royal Manchester Children’s Hospital, UK

Allergy/Immunology

Oscar Palomares

Complutense University of Madrid

Martin Wagenmann

Head of Rhinology, Allergy, and Endoscopic Skull Base Surgery and Head of the Research Laboratory in the ENT Department | University Hospital of Düsseldorf, Germany

Eugenio De Corso

Adjunct Professor of Otorhinolaryngology | Catholic University of the Sacred Heart, Milan, Italy

Allergy/Immunology

Leonard Bacharier

Janie Robinson and John Moore Lee Chair of Pediatrics and Director of Center for Pediatric Asthma Research | Vanderbilt University, Tennessee, United States

Allergy/Immunology

Antonella Cianferoni

Associate Professor in Pediatrics | Perelman School of Medicine, University of Pennsylvania; Medical Director of the Food Allergy Immunotherapy Program | Children’s Hospital of Philadelphia, Pennsylvania, United States

Monika Gappa

Professor of Pediatrics and Director | Children’s Hospital, Evangelisches Krankenhaus, Düsseldorf, Germany

Related resources

EAACI 2023 | Recognizing EoE in the Allergy Clinic

Gastroenterology

EAACI 2023 | Recognizing EoE in the Allergy Clinic

EAACI 2023 | Pediatric Type 2 Inflammatory Disease Progression

Type 2 Inflammation

EAACI 2023 | Pediatric Type 2 Inflammatory Disease Progression

EAACI 2023 | Biologics in CRSwNP: Comparative Efficacy and Real-World Effectiveness

EAACI 2023 | Biologics in CRSwNP: Comparative Efficacy and Real-World Effectiveness

EAACI 2023 | Pediatric Severe Asthma: Why Lung Function Matters

EAACI 2023 | Pediatric Severe Asthma: Why Lung Function Matters

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region